JP2018525413A - ユーイングファミリー腫瘍を治療する組成物及び方法 - Google Patents

ユーイングファミリー腫瘍を治療する組成物及び方法 Download PDF

Info

Publication number
JP2018525413A
JP2018525413A JP2018510098A JP2018510098A JP2018525413A JP 2018525413 A JP2018525413 A JP 2018525413A JP 2018510098 A JP2018510098 A JP 2018510098A JP 2018510098 A JP2018510098 A JP 2018510098A JP 2018525413 A JP2018525413 A JP 2018525413A
Authority
JP
Japan
Prior art keywords
tyrosine kinase
kinase inhibitor
biguanide compound
imatinib
metformin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018510098A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525413A5 (enExample
Inventor
ホン チャオ
ホン チャオ
ステファン ティー．シー． ウォン
ステファン ティー．シー． ウォン
Original Assignee
ザ メソディスト ホスピタル
ザ メソディスト ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ メソディスト ホスピタル, ザ メソディスト ホスピタル filed Critical ザ メソディスト ホスピタル
Publication of JP2018525413A publication Critical patent/JP2018525413A/ja
Publication of JP2018525413A5 publication Critical patent/JP2018525413A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018510098A 2015-08-24 2016-08-22 ユーイングファミリー腫瘍を治療する組成物及び方法 Pending JP2018525413A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562209197P 2015-08-24 2015-08-24
US62/209,197 2015-08-24
US201562209645P 2015-08-25 2015-08-25
US62/209,645 2015-08-25
PCT/US2016/047984 WO2017035057A1 (en) 2015-08-24 2016-08-22 Compositions and methods for treating ewing family tumors

Publications (2)

Publication Number Publication Date
JP2018525413A true JP2018525413A (ja) 2018-09-06
JP2018525413A5 JP2018525413A5 (enExample) 2019-10-03

Family

ID=58101236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018510098A Pending JP2018525413A (ja) 2015-08-24 2016-08-22 ユーイングファミリー腫瘍を治療する組成物及び方法

Country Status (7)

Country Link
US (1) US10765675B2 (enExample)
EP (1) EP3340978A4 (enExample)
JP (1) JP2018525413A (enExample)
CN (1) CN106714795A (enExample)
CA (1) CA2995642A1 (enExample)
TW (1) TW201717926A (enExample)
WO (1) WO2017035057A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108034726B (zh) * 2018-01-18 2021-07-30 四川大学华西医院 检测mlh1表达水平的试剂在制备肿瘤靶向药敏感性检测试剂盒中的用途
WO2022093789A1 (en) * 2020-10-27 2022-05-05 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of apex, alone and in combination with other cancer drugs to inhibit growth of cancer cells
WO2025097033A1 (en) * 2023-11-01 2025-05-08 City Of Hope Metformin combination therapy for use in cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641940A4 (en) 2003-07-01 2009-09-02 Mor Research Applic Ltd DETERMINING PROGNOSIS IN PATIENTS WITH EWING SARCOMA BY GENETIC PROFILES
WO2008089034A2 (en) 2007-01-11 2008-07-24 Kemia, Inc. Cytokine inhibitors
ES2594402T3 (es) * 2009-10-21 2016-12-20 Agios Pharmaceuticals, Inc. Métodos y composiciones para trastornos relacionados con la proliferación celular
EP2509600B1 (en) 2009-12-09 2017-08-02 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
EP3024456A4 (en) 2013-07-26 2017-04-12 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAO, JOSEPH ET AL., ANTICANCER RESEARCH, vol. 30, no. 2, JPN6020022201, February 2010 (2010-02-01), pages 547 - 552, ISSN: 0004451522 *
CURVELLO, R. ET AL., ANNALS OF ONCOLOGY, vol. 24, no. 1, JPN6020022202, March 2013 (2013-03-01), ISSN: 0004451523 *
GAROFALO, CECILIA ET AL., PLOS ONE, vol. Vol. 8, Issue 12, JPN6020022204, December 2013 (2013-12-01), pages 83832, ISSN: 0004292250 *

Also Published As

Publication number Publication date
US20180243299A1 (en) 2018-08-30
US10765675B2 (en) 2020-09-08
TW201717926A (zh) 2017-06-01
CN106714795A (zh) 2017-05-24
EP3340978A1 (en) 2018-07-04
WO2017035057A1 (en) 2017-03-02
EP3340978A4 (en) 2019-04-10
CA2995642A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
JP5249239B2 (ja) 癌の治療における葉酸代謝拮抗剤の併用
JP2013542965A (ja) 腫瘍の治療方法
JP2018531273A (ja) がんを治療するためのｍｄｍ２阻害剤の投与計画
JP2018531273A6 (ja) がんを治療するためのｍｄｍ２阻害剤の投与計画
JP2018525413A (ja) ユーイングファミリー腫瘍を治療する組成物及び方法
WO2023010107A1 (en) Treating cancers with combinations of spironolactone and acylfulvenes
Jang et al. Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models
US9901594B2 (en) Pharmaceutical composition and uses thereof
US10188666B2 (en) Dendrogenin A and antineoplastic agents for the treatment of chemosensitive or chemoresistant tumors
US20230095428A1 (en) [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer
US20140275214A1 (en) Custirsen treatment with reduced toxicity
WO2010081662A2 (en) Methods for identifying patients who will respond well to cancer treatment
US20210379095A1 (en) Methods and Combination Therapy to Treat Biliary Tract Cancer
Orlandi et al. Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells
US20230097085A1 (en) [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer
US20230102483A1 (en) [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer
JP2019123671A (ja) 前立腺がんの予防又は治療剤
Jeong et al. Bevacizumab plus erlotinib in advanced solid cancers with Krebs cycle gene mutations: A multicenter phase II study (BRISK; KCSG AL22-16)
Hayashi et al. 37eP Translational preclinical evaluation of zipalertinib in an amivantamab-resistant EGFR exon 20 insertion NSCLC model
Macia et al. 39eP Adoption of Bayesian optimal interval (BOIN) design in phase I oncology trials: Trends and challenges
HK40038981A (en) Methods and combination therapy to treat biliary tract cancer
WO2024054898A1 (en) Onvansertib and parp inhibitor combination
WO2025049904A1 (en) Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
Symonds et al. Principles of management of patients with cancer
BR122024025393A2 (pt) Uso de um composto, kit e composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180413

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20180413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200630

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210302